miR‐210 as a therapeutic target in diabetes‐associated endothelial dysfunction
British Journal of Pharmacology · 2025-01 · 182 (2) · 417-431
DOI: 10.1111/bph.17329 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 14.10.2024. Verfasst von Aida Collado und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: MicroRNAs, Diabetes Mellitus, Type 2, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Endothelium, Vascular. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: EFSD/Novo Nordisk Foundation Future Leaders Award, Swedish Heart and Lung Foundation (Hjärt-Lungfonden), Swedish Research Council (Vetenskapsrådet).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background and Purpose MicroRNA (miR)‐210 function in endothelial cells and its role in diabetes‐associated endothelial dysfunction are not fully understood. We aimed to characterize the miR‐210 function in endothelial cells and study its therapeutic potential in diabetes. Experimental Approach Two different diabetic mouse models ( db/db and Western diet‐induced), miR‐210 knockout and transgenic mice, isolated vessels and human endothelial cells were used. Key Results miR‐210 levels were lower in aortas isolated from db/db than in control mice. Endothelium‐dependent relaxation (EDR) was impaired in aortas from miR‐210 knockout mice, and this was restored by inhibiting miR‐210 downstream protein tyrosine phosphatase 1B (PTP1B), mitochondrial glycerol‐3‐phosphate dehydrogenase 2 (GPD2), and mitochondrial oxidative stress. Inhibition of these pathways also improved EDR in both diabetic mouse models. High glucose reduced miR‐210 levels in endothelial cells and impaired EDR in mouse aortas, effects that were reversed by overexpressing miR‐210. However, plasma miR‐210 levels were not affected in individuals with type 2 diabetes (T2D) following improved glycaemic status. Of note, genetic overexpression using miR‐210 transgenic mice and pharmacological overexpression using miR‐210 mimic in vivo ameliorated endothelial dysfunction in both diabetic mouse models by decreasing PTP1B, GPD2 and oxidative stress. Genetic overexpression of miR‐210 altered the aortic transcriptome, decreasing genes in pathways involved in oxidative stress. miR‐210 mimic restored decreased nitric oxide production by high glucose in endothelial cells. Conclusion and Implications This study unravels the mechanisms by which down‐regulated miR‐210 by high glucose induces endothelial dysfunction in T2D and demonstrates that miR‐210 serves as a novel therapeutic target. LINKED ARTICLES This article is part of a themed issue Non‐coding RNA Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.2/issuetoc
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
- Division of Cardiovascular Medicine, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
- Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, San Donato Milanese, Italy.
- Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Zhichao Zhou
Förderung
- EFSD/Novo Nordisk Foundation Future Leaders Award
- Swedish Heart and Lung Foundation (Hjärt-Lungfonden)
- Swedish Research Council (Vetenskapsrådet)
- Diabetes Research & Wellness Foundation
- Stockholm County Council ALF (Stockholms Läns Landsting)
- EFSD/Sanofi European Diabetes Research Programme in Macrovascular Complications
- Karolinska Institutet KID
- Karolinska Institutet
Zitieren
APA
Collado, A., Jiao, T., Kontidou, E., Carvalho, L. R. R. A., Chernogubova, E., Yang, J., Zaccagnini, G., Zhao, A., Tengbom, J., Zheng, X., Rethi, B., Alvarsson, M., Catrina, S. B., Mahdi, A., Carlström, M., Martelli, F., Pernow, J., & Zhou, Z. (2025). miR‐210 as a therapeutic target in diabetes‐associated endothelial dysfunction. British Journal of Pharmacology, 182(2), 417-431. https://doi.org/10.1111/bph.17329
Vancouver
Collado A, Jiao T, Kontidou E, Carvalho LRRA, Chernogubova E, Yang J, et al. miR‐210 as a therapeutic target in diabetes‐associated endothelial dysfunction. British Journal of Pharmacology. 2025;182(2):417-431. doi:10.1111/bph.17329
BibTeX
@article{Collado2025,
author = {Collado, Aida and Jiao, Tong and Kontidou, Eftychia and Carvalho, Lucas Rannier Ribeiro Antonino and Chernogubova, Ekaterina and Yang, Jiangning and Zaccagnini, Germana and Zhao, Allan and Tengbom, John and Zheng, Xiaowei and Rethi, Bence and Alvarsson, Michael and Catrina, Sergiu-Bogdan and Mahdi, Ali and Carlström, Mattias and Martelli, Fabio and Pernow, John and Zhou, Zhichao},
title = {miR‐210 as a therapeutic target in diabetes‐associated endothelial dysfunction},
journal = {British Journal of Pharmacology},
year = {2025},
volume = {182},
number = {2},
pages = {417--431},
doi = {10.1111/bph.17329}
}
EUVIMED